ResMed Q1 constant-currency revenue growth slows to 7% while GLP-1 users show higher CPAP initiation

What happened

ResMed reported first-quarter fiscal 2027 constant-currency revenue growth of 7%, decelerating from the 10% core growth achieved in fiscal 2026 and below the high-single-digit device growth implied by the bull case. The company also highlighted observational data indicating patients on GLP-1 drugs are 11% more likely to start CPAP therapy, reinforcing the narrative that weight-loss medications widen rather than shrink the diagnostic funnel. This latest print contrasts with the prior fiscal year, when device revenue grew 9% and masks 13%, and suggests either normalizing comparisons or slower conversion from the expanded funnel of NightOwl, VirtuOx, and wearable referrals. The market continues to treat GLP-1s as a tailwind, but direct proof of durable PAP starts and resupply conversion remains undisclosed, leaving the thesis reliant on funnel metrics rather than hard therapy revenue. With the stock trading near $222, modestly above the $205 attractive entry, the new data does not warrant a rating change but sharpens the need to monitor growth durability and competitive dynamics.

Implication

The 7% constant-currency growth in Q1 is a step down from the double-digit rates that underpinned the bull thesis, so the next one to two quarters must show stabilization or reacceleration in device and mask segments to validate the funnel expansion story. The GLP-1 conversion data is encouraging but remains observational, and management has still not disclosed PAP starts or therapy-to-resupply conversion, which keeps the investment case dependent on leading indicators rather than hard evidence. At the current price around $222, the stock already discounts continued demand generation from wearables, home testing, and GLP-1 awareness, leaving limited upside unless growth returns to above 8% with stable gross margins near 61%. The Astral ventilator recall and the potential for Philips to regain U.S. selling clearance remain key risks that could pressure pricing and volumes, particularly if they coincide with slower organic demand. Therefore, existing holders can maintain positions but new money should wait for a better entry near $205 or for two consecutive quarters of device and mask growth above 8%, which would signal genuine conversion of the enlarged funnel into durable revenue.

Thesis delta

The core thesis remains intact but faces a fresh test: Q1 constant-currency growth of 7% is below the FY26 exit rate and suggests the funnel tailwind may be translating into revenue more slowly than hoped. The GLP-1 data showing an 11% higher CPAP initiation rate supports the long-term demand expansion argument, but without conversion metrics, the evidence is still circumstantial. Consequently, we maintain a WAIT rating with an attractive entry at $205, but the probability of the bull case (device growth >10%) may be trimmed if deceleration persists into the next quarter.